2. Academic Validation
  3. Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma

Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma

  • Cell Death Discov. 2023 Jan 25;9(1):30. doi: 10.1038/s41420-023-01319-y.
Lina Wei 1 2,  Xiaohong Ma 2 3,  Yixin Hou 1 2,  Tianyi Zhao 1 2,  Rui Sun 1 2,  Chunping Qiu 1,  Yao Liu 1 2,  Ziyi Qiu 1 2,  Zhiming Liu 4,  Jie Jiang 5
Affiliations

Affiliations

  • 1 Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, 250012, Jinan, Shandong, China.
  • 2 Gynecology Oncology Key Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong, China.
  • 3 Department of Gynecology and Obstetrics, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, 20 Yuhuangding East Road, 264000, Yantai, Shandong, China.
  • 4 Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, 250012, Jinan, Shandong, China. [email protected].
  • 5 Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, 107 Wenhua Xi Road, 250012, Jinan, Shandong, China. [email protected].
PMID: 36693834 DOI: 10.1038/s41420-023-01319-y
Abstract

Progestin resistance is a problem for patients with endometrial carcinoma (EC) who require conservative treatment with progestin, and its underlying mechanisms remain unclear. YAP and TAZ (YAP/TAZ), downstream transcription coactivators of Hippo pathway, promote viability, metastasis and also drug resistance of malignant tumors. According to our microarray analysis, YAP/TAZ were upregulated in progestin resistant IshikawaPR cell versus progestin sensitive Ishikawa cell, which implied that YAP/TAZ may be a vital promotor of resistance to progestin. We found YAP/TAZ had higher expression levels among the resistant tissues than sensitive tissues. In addition, knocking down YAP/TAZ decreased cell viability, inhibited cell migration and invasion and increased the sensitivity of IshikawaPR cell to progestin. On the contrary, overexpression of YAP/TAZ increased cell proliferation, metastasis and promoted progestin resistance. We also confirmed YAP/TAZ were involved in progestin resistant process by regulating PI3K-Akt pathway. Furthermore, Verteporfin as an inhibitor of YAP/TAZ could increase sensitivity of IshikawaPR cells to progestin in vivo and in vitro. Our study for the first time indicated that YAP/TAZ play an important role in progestin resistance by regulating PI3K-Akt pathway in EC, which may provide ideas for clinical targeted therapy of progestin resistance.

Figures
Products